Demographic and Serologic Factors Predict Rheumatoid Arthritis-Associated Interstitial Lung Disease

Abstract

Demographic and Serologic Factors Predict Rheumatoid Arthritis-Associated Interstitial Lung Disease

Abstract

Purpose: Interstitial lung disease (ILD) stands as a prominent reason of morbidity and mortality in rheumatoid arthritis (RA). Certain demographic and serologic elements have been attributed in the risk of RA-ILD; however, the available data may not be sufficient to fully clarify this association. Our objective was to analyze the relationship of demographic features and serologic factors with RA-ILD. Methods: We examined clinical data from RA patients between January 2015-January 2020. Chest CT examinations were assessed for ILD. The association between age, gender, smoking, RF and anti-CCP titers and the existence of RA-ILD was analyzed. The same factors were analyzed for the existence of usual interstitial pneumonia (UIP) pattern in RA-ILD patients. Results: RA patients with ILD were notably older (p=0.005), male (p<0.001), and smokers (p=0.027). Higher RF titers were found in RA-ILD group (p=0.022). Although anti-CCP rates and titers were elevated in RA-ILD patients, the variation was not significant. Male sex was linked with the UIP pattern (p=0.029), but other factors did not vary significantly between UIP and non-UIP patterns. Conclusion: Advanced age, being male, smoking, and elevated RF titers were spotted as significant indicators of RA-ILD. Except for male gender, no significant risk factor predicted UIP pattern.

Keywords

• Rheumatoid arthritis
• interstitial lung disease
• smoking
• rheumatoid factor
• anti-cyclic citrullinated peptide

References

1. Suda T. Up-to-Date Information on Rheumatoid Arthritis-Associated Interstitial Lung Disease. Clin Med Insights Circ Respir Pulm Med 2016;9:155-62.
2. Koduri G, Norton S, Young A, et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford) 2010;49(8):1483-1489.
3. Kadura S, Raghu G. Rheumatoid arthritis-interstitial lung disease: Manifestations and current concepts in pathogenesis and management. Eur Respir Rev 2021;30:210011.
4. Chen J, Shi Y, Wang X, Huang H, Ascherman D. Asymptomatic preclinical rheumatoid arthritis-associated interstitial lung disease. Clin Dev Immunol 2013;2013:406927.
5. Restrepo JF, del Rincón I, Battafarano DF, Haas RW, Doria M, Escalante A. Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis. Clin Rheumatol 2015;34(9):1529-1536.
6. Dai Y, Wang W, Yu Y, Hu S. Rheumatoid arthritis-associated interstitial lung disease: an overview of epidemiology, pathogenesis and management. Clin Rheumatol 2021;40(4):1211-1220.
7. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 2001;56(8):622-627.
8. Assayag D, Elicker BM, Urbania TH, et al. Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Radiology 2014;270(2):583-588.

9. Jacob J, Hirani N, van Moorsel CHM, et al. Predicting outcomes in rheumatoid arthritis related interstitial lung disease. Eur Respir J 2019;53(1):1800869.
10. Kakutani T, Hashimoto A, Tominaga A, et al. Related factors, increased mortality and causes of death in patients with rheumatoid arthritis-associated interstitial lung disease. Mod Rheumatol 2020;30(3):458–64.
11. Bernstein EJ, Barr RG, Austin JHM, et al. Rheumatoid arthritis-associated autoantibodies and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis. Thorax 2016;71(12):1082-1090.
12. Zhu J, Zhou Y, Chen X, Li J. A metaanalysis of the increased risk of rheumatoid arthritis-related pulmonary disease as a result of serum anticitrullinated protein antibody positivity. J Rheumatol 2014;41(7):1282-1289.
13. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62(9):2569-2581.
14. Zhang Y, Li H, Wu N, Dong X, Zheng Y. Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol 2017;36(4):817-823.
15. Kelly CA, Saravanan V, Nisar M, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study. Rheumatology (Oxford) 2014;53(9):1676-1682.
16. Azam AT, Odeyinka O, Alhashimi R, et al. Rheumatoid Arthritis and Associated Lung Diseases: A Comprehensive Review. Cureus 2022;14(2):e22367.
17. Mori S, Koga Y, Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med 2012;106(11):1591-1599.
18. Saag KG, Kolluri S, Koehnke RK, et al. Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthritis Rheum 1996;39(10):1711-1719.
19. Hoovestol RA, Mikuls TR. Environmental exposures and rheumatoid arthritis risk. Curr Rheumatol Rep 2011;13(5):431-439.
20. Gochuico BR, Avila NA, Chow CK, et al. Progressive Preclinical Interstitial Lung Disease in Rheumatoid Arthritis. Arch Intern Med 2008;168(2):159–166.
21. Bongartz T, Cantaert T, Atkins SR, et al. Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology (Oxford) 2007;46(1):70-75.
22. Correia CS, Briones MR, Guo R, Ostrowski RA. Elevated anti-cyclic citrullinated peptide antibody titer is associated with increased risk for interstitial lung disease. Clin Rheumatol 2019;38(4):1201-1206.
23. Giles JT, Danoff SK, Sokolove J, et al. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis 2014;73(8):1487-1494.
24. Mori S, Koga Y, Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med 2012;106(11):1591–1599.
25. Inui N, Enomoto N, Suda T, Kageyama Y, Watanabe H CK. Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. Clin Biochem 2008;41:1074–1077.
26. Ascherman DP. Interstitial lung disease in rheumatoid arthritis. Curr Rheumatol Rep 2010;12(5):363–369.
27. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010;35(6):1322–1328.